Swiss biotech Actelion CEO Jean-Paul Clozel endorses independence not acquisition - CEOWORLD magazine
Clozel's CHF1bn Actelion Spin-Out Idorsia Awaits Janssen Buy-In :: Scrip
Idorsia, a small company with a big portfolio says Martine Clozel
How is Actelion Spin-Off Idorsia Doing One Year Later?
Johnson & Johnson Chief Scientific Officer Pharmaceuticals Paul Stoffels (L) e Actelion CEO e fondatore Jean-Paul Clozel partecipano a una conferenza stampa presso la sede centrale di Actelion ad Allschwil, Svizzera, 26
Molecular Millionaire: Jean-Paul Clozel of Actelion
Actelion spinout Idorsia hits goals in insomnia phase 2, sparking stock rise and talk of partnering up for pivotal trial | Fierce Biotech
Actelion's Fate May Rest on Structure, Not Price, as Clozel Holds Firm - TheStreet
Jean-Paul Clozel, CEO Actelion - YouTube
Actelion - Wikipedia
Der Manager des Jahres heisst Jean-Paul Clozel | Finanz und Wirtschaft
J&J Makes Big Bet on Rare Disease With $30 Billion Actelion Deal - Bloomberg
Actelion in $360M settlement - San Francisco Business Times
Actelion's Jean-Paul Clozel aims to keep group's independence | Financial Times
Was plant das Ehepaar Clozel? | NZZ
Actelion: Die Knackpunkte eines Deals mit Johnson & Johnson | Tages-Anzeiger
Jean-Paul Clozel | EY - Global
PharmaBoardroom - Jean-Paul Clozel - CEO, Idorsia (October 2017)
Jean-Paul Clozel
J&J Woos Billionaire Doctors Who Don't Need Cash in Actelion Bid - Bloomberg
38 Jean Paul Clozel Photos and Premium High Res Pictures - Getty Images
Biotech: Jean-Paul Clozel kämpft bei Idorsia mit Gegenwind
Profile: Jean-Paul Clozel | Nature Biotechnology
Jean-Paul Clozel – mit Herzblut für Actelion - Rendez-vous - SRF
Who wants to be a billionaire? Not Actelion's founder and CEO, if it means selling out | Fierce Pharma
Jean-Paul Clozel
